S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:SGMO

Sangamo Therapeutics News Headlines

$15.75
-0.44 (-2.72 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.73
Now: $15.75
$16.79
50-Day Range
$9.28
MA: $14.20
$18.18
52-Week Range
$4.81
Now: $15.75
$19.43
Volume1.13 million shs
Average Volume1.52 million shs
Market Capitalization$2.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines Today

Source:
SourceHeadline
Sangamo Therapeutics (NASDAQ:SGMO) Raised to C- at TheStreetSangamo Therapeutics (NASDAQ:SGMO) Raised to C- at TheStreet
marketbeat.com - December 24 at 7:13 AM
BidaskClub Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to "Hold"BidaskClub Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to "Hold"
marketbeat.com - October 8 at 4:14 AM
Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to Hold by BidaskClubSangamo Therapeutics (NASDAQ:SGMO) Upgraded to Hold by BidaskClub
marketbeat.com - September 11 at 5:38 PM
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by BidaskClub to SellSangamo Therapeutics (NASDAQ:SGMO) Downgraded by BidaskClub to Sell
marketbeat.com - August 29 at 9:43 AM
Sangamo Therapeutics (NASDAQ:SGMO) Cut to "Sell" at Zacks Investment ResearchSangamo Therapeutics (NASDAQ:SGMO) Cut to "Sell" at Zacks Investment Research
marketbeat.com - August 7 at 6:42 AM
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Years EstimatesSangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Year's Estimates
finance.yahoo.com - January 8 at 8:27 AM
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung LeeSangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
finance.yahoo.com - January 6 at 4:23 PM
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Stifel NicolausSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Stifel Nicolaus
americanbankingnews.com - January 5 at 6:16 PM
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceSangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 8:47 AM
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 7.8%Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 7.8%
americanbankingnews.com - December 29 at 8:12 PM
Sangamo Therapeutics (NASDAQ:SGMO) Sets New 52-Week High at $18.96Sangamo Therapeutics (NASDAQ:SGMO) Sets New 52-Week High at $18.96
americanbankingnews.com - December 28 at 12:50 PM
Sangamo TherapeuticsSangamo Therapeutics
fool.com - December 25 at 11:21 PM
First Week of SGMO August 2021 Options TradingFirst Week of SGMO August 2021 Options Trading
nasdaq.com - December 18 at 2:22 PM
Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?
finance.yahoo.com - December 14 at 12:50 PM
SGMO Crosses Below Key Moving Average LevelSGMO Crosses Below Key Moving Average Level
nasdaq.com - December 7 at 4:36 PM
Pfizer, Sangamo Report Encouraging Findings From Phase 1/2 Study Of Giroctocogene FitelparvovecPfizer, Sangamo Report Encouraging Findings From Phase 1/2 Study Of Giroctocogene Fitelparvovec
nasdaq.com - December 7 at 11:35 AM
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene TherapyPfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
finance.yahoo.com - December 7 at 11:35 AM
How Much Did Sangamo Therapeutics(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years?How Much Did Sangamo Therapeutics'(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years?
finance.yahoo.com - November 30 at 4:23 PM
Pfizer (PFE) Begins Phase III Study on Hemophilia CandidatePfizer (PFE) Begins Phase III Study on Hemophilia Candidate
finance.yahoo.com - November 24 at 2:48 PM
Sangamo Therapeutics, Inc. to Host Earnings CallSangamo Therapeutics, Inc. to Host Earnings Call
marketwatch.com - November 6 at 10:15 PM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 1:04 AM
Sangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call TranscriptSangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call Transcript
fool.com - November 4 at 11:39 PM
Sangamo Therapeutics EPS beats by $0.24, beats on revenueSangamo Therapeutics EPS beats by $0.24, beats on revenue
seekingalpha.com - November 4 at 8:03 PM
Sangamo Therapeutics Q3 2020 Earnings PreviewSangamo Therapeutics Q3 2020 Earnings Preview
seekingalpha.com - November 3 at 11:20 PM
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and WebcastSangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
finance.yahoo.com - October 28 at 7:01 PM
Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should KnowWill Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 28 at 2:01 PM
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their HoldingsSangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their Holdings
finance.yahoo.com - October 18 at 2:43 AM
Sizing Up Sangamo TherapeuticsSizing Up Sangamo Therapeutics
seekingalpha.com - October 13 at 7:48 AM
Pfizer commences late-stage study of hemophilia A gene therapyPfizer commences late-stage study of hemophilia A gene therapy
seekingalpha.com - October 7 at 7:23 AM
CRISPR startup Scribe Therapeutics lands big Biogen dealCRISPR startup Scribe Therapeutics lands big Biogen deal
bizjournals.com - October 6 at 8:27 PM
Sangamo Therapeutics, Inc. (0R1D.L)Sangamo Therapeutics, Inc. (0R1D.L)
uk.finance.yahoo.com - September 26 at 4:12 AM
Sangamo Therapeutics, Inc. (SGMO)Sangamo Therapeutics, Inc. (SGMO)
au.finance.yahoo.com - September 25 at 10:21 PM
Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key ThresholdSangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - September 15 at 12:24 PM
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of DirectorsSangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
finance.yahoo.com - September 11 at 1:33 PM
Sangamo Therapeutics Getting Closer To Key Technical BenchmarkSangamo Therapeutics Getting Closer To Key Technical Benchmark
finance.yahoo.com - September 10 at 12:28 PM
How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO?How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO?
finance.yahoo.com - September 1 at 7:54 PM
BioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene TherapyBioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene Therapy
finance.yahoo.com - August 19 at 12:37 PM
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare ConferenceSangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 10 at 10:17 AM
Sangamo Therapeutics +3.1% despite Q2 missSangamo Therapeutics +3.1% despite Q2 miss
seekingalpha.com - August 6 at 6:44 PM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 6 at 1:24 AM
Sangamo Therapeutics Inc (SGMO) Q2 2020 Earnings Call TranscriptSangamo Therapeutics Inc (SGMO) Q2 2020 Earnings Call Transcript
nasdaq.com - August 6 at 1:24 AM
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial ResultsSangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
finance.yahoo.com - August 5 at 8:24 PM
Sangamo Therapeutics Q2 Earnings PreviewSangamo Therapeutics Q2 Earnings Preview
seekingalpha.com - August 4 at 7:21 PM
Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO)Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO)
finance.yahoo.com - August 3 at 2:21 PM
Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO) ?Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO) ?
finance.yahoo.com - August 3 at 2:21 PM
Sangamo, Novartis Make Gene Therapy Deal for Brain DisordersSangamo, Novartis Make Gene Therapy Deal for Brain Disorders
www.msn.com - July 31 at 12:42 AM
Sangamo teams up with Novartis in neurodevelopmental disordersSangamo teams up with Novartis in neurodevelopmental disorders
seekingalpha.com - July 30 at 9:41 AM
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and WebcastSangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
finance.yahoo.com - July 29 at 10:27 PM
Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?
finance.yahoo.com - July 29 at 5:27 PM
4 More Biotechs Break From IPO Starting Gate4 More Biotechs Break From IPO Starting Gate
finance.yahoo.com - July 27 at 6:42 PM
Sangamo Therapeutics IncSangamo Therapeutics Inc
www.bloomberg.com - July 26 at 10:11 PM
How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own?How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own?
finance.yahoo.com - July 9 at 12:00 PM
Sangamo Announces R&D Organization ChangesSangamo Announces R&D Organization Changes
finance.yahoo.com - June 24 at 9:11 AM
Pfizer and Sangamos Gene Therapy Continues to Help Patients with Hemophilia in Clinical TrialPfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial
www.fool.com - June 18 at 6:39 PM
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene TherapyPfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
finance.yahoo.com - June 18 at 6:39 PM
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.